Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of ABT-494 in adults with moderate to severe atopic dermatitis
2016-002451-21Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of upadacitinib in atopic dermatitis (AD) (4 arms), sponsored by AbbVie Inc. Primary endpoint: Mean percent change from baseline in EASI score at Week 16. Started Oct 2016; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2016-002451-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002451-21.